Top 20 Life Science VC Funds & Investors in Australia (June 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Main Sequence Ventures
VC Fund
|
3 | Australia, United States, Philippines | Seed, Series A, Series B | Software, Artificial Intelligence, Manufacturing | $1M–$73M |
|
Tin Alley Ventures
VC Fund
|
2 | Australia, Philippines | Pre-Seed, Seed | Biotechnology, Medical, Health Care | $2.6M–$3M |
|
Possible Ventures
VC Fund
|
1 | Germany, Australia, United States | Seed, Pre-Seed, Series A | Software, Biotechnology, Information Technology | $549k–$44M |
|
Churchill Asset Management
VC Fund
|
1 | United States | Debt Financing, Private Equity | Health Care, Pet, Dental | |
|
Uniseed
VC Fund
|
1 | Australia, United States, United Kingdom | Series A, Seed, Series B | Biotechnology, Health Care, Manufacturing | $471k–$22M |
|
Uniseed Ventures
VC Fund
|
1 | Australia, United States, United Kingdom | Series A, Seed | Biotechnology, Health Care, Manufacturing | $381k–$16M |
|
OneVentures
VC Fund
|
1 | Australia, United States, Israel | Series A, Debt Financing | Software, Health Care, Biotechnology | $1M–$20M |
|
Bioplatforms Australia
VC Fund
|
1 | Australia | Pre-Seed | AgTech, Farming, Agriculture | |
|
Antler
VC Fund
|
1 | Singapore, Australia, United Kingdom | Pre-Seed, Seed, Series A | Software, Artificial Intelligence, Information Technology | $104k–$29M |
|
Skalata
VC Fund
|
1 | Australia, United States, United Kingdom | Pre-Seed, Seed | Software, Education, Information Technology | $135k–$2.3M |
|
Riverlane Capital
VC Fund
|
1 | Australia | Series A | Life Science, Biotechnology, Venture Capital | |
|
Medical Research Commercialisation Fund (MRCF)
VC Fund
|
1 | Australia, United States, United Kingdom | Series A, Seed, Series B | Biotechnology, Health Care, Medical | $1.3M–$16M |
|
Alberici
VC Fund
|
1 | Australia | Seed | Real Estate, Life Science, Property Management | |
|
The March Group
VC Fund
|
1 | United States | Seed, Series A, Series C | SaaS, Energy, Retail | $4.7M–$33M |
|
Alium Capital
VC Fund
|
1 | Australia, United States, Singapore | Series A, Series B, Seed | Software, Financial Services, Apps | $500k–$465M |
|
Breakthrough Victoria
VC Fund
|
1 | Australia, United States, Philippines | Seed, Series A | Health Care, Manufacturing, Biotechnology | $708k–$36M |
|
Accelerating Commercialisation - AusIndustry
VC Fund
|
1 | Australia | Grant, Pre-Seed | Software, Mining, Hardware | |
|
Catalio Capital Management
VC Fund
|
1 | United States, Switzerland, Israel | Series A, Series B | Biotechnology, Health Care, Life Science | $18M–$150M |
|
Flintco, LLC
VC Fund
|
1 | Australia | Seed | Real Estate, Life Science, Property Management | |
|
AbbVie Biotech Ventures
VC Fund
|
1 | United States, China, Italy | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $6M–$115M |
| Access all 39 VC funds in Australia Life Science startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
We work with inventors who are building something hard from their unique expertise in science. These inventors are building the industries that will thrive for the decades to come. We have a unique working model to accelerate a company's pathway to scale.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Manufacturing
- Stage:Seed, Series A, Series B
- Geography: Australia, United States, Philippines
Investor stats
- Total investments: 125
- Round size: Seed $1M–$7.1M; Series A $4.5M–$29M; Series B $13M–$73M
- Lead/follow: 42% lead, 58% follow
- Last fund: Likely still investing — raised $303M in 2023
Portfolio highlights
- Endua — Endua is building the next generation of clean energy deep storage to power communities, remote industries and off-grid infrastructure at the flick of a switch - all day and night
- Arlula — Arlula provides a single integration point for a global network of satellite imagery. Sign up today and get BETA access to our API.
- QuintessenceLabs — Quantum cyberattacks can break current encryption in minutes! Get protected with QuintessenceLabs quantum key distribution, generation, and management.
Tin Alley Ventures collaborates with companies and researchers in the University of Melbourne's ecosystem to invest in & support world-changing businesses.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Pre-Seed, Seed
- Geography: Australia, Philippines
Investor stats
- Total investments: 5
- Round size: Pre-Seed $2.6M–$3M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- i14 — We are i14 — we sit at the intersection of Computational Cognitive Science and AI research, and have developed a new class of models called Laplace Sequence Models that are an order of magnitude faster and more efficient and multiples more accurate than the transformer. We’ve also built a foundation model platform that allows organisations tocreate private, domain-specific expert models deployable across any environment (on-prem, at the edge, on device, in a private cloud, or hosted by i14). Our research lab continues to push beyond many of the limitations of current AI, and has a host of research projects which are continually integrated to update our foundation model platform. We recently closed a $4M initial round and are preparing for the next round.
- Mirugen — Mirugen is a preclinical biotechnology company identifying the optimal set of cellular instructions to ask one cell type to become another.
- Cell Bauhaus — Cell Bauhaus uses mathematical and computer modeling to understand, predict, and modify living cell behavior, aiming to expedite sustainable solutions to humanity's pressing issues.
Possible Ventures backs ambitious teams building frontier technology to positively impact society. We invest globally in the early stages, actively supporting founders via our collective of global entrepreneurs.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Pre-Seed, Series A
- Geography: Germany, Australia, United States
Investor stats
- Total investments: 163
- Round size: Seed $1.6M–$10M; Pre-Seed $549k–$3.8M; Series A $9.5M–$44M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- Eden Brew — Eden Brew is a ground-breaking new way to enjoy dairy products sustainably and nutritiously.
- Auriga Space — Next-generation space launch company providing frequent, sustainable and affordable transport to low Earth orbit
- InSpacePropulsion Technologies — Cost-effective, robust, and quickly available propulsion solutions, based on 10+ years of R&D and 40 years of combined experience in space propulsion.
Churchill is a leading capital provider for private equity-owned, middle market companies. We provide first lien, unitranche, second lien and mezzanine debt, in addition to equity co-investments, secondary solutions and private equity fund commitments.
Show more...Investment focus
- Industry: Health Care, Pet, Dental
- Stage:Debt Financing, Private Equity
- Geography: United States
Investor stats
- Total investments: 5
- Lead/follow: 40% lead, 60% follow
- Last fund: Likely still investing — fund raised in 2021
Portfolio highlights
- Proto Axiom — Early-stage funding to growth capital, we guide scientific breakthroughs from proof-of-concept to commercial success. Our hands-on approach to support Australian research is a first-in-country model.
- Mosaic Dental Collective — Mosaic Dental Collective provides administrative and business operations support to dental practices. They are a multi-specialty group where doctors make decisions and are supported by an experienced professional management team.
- Heartland Veterinary Partners — Heartland Veterinary Partners purchases practices, providing operational support for payroll, HR, marketing, and more. Veterinarians can focus on patient care.
Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff ofthese organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund.A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011.With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position.On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million).Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network.The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Manufacturing
- Stage:Series A, Seed, Series B
- Geography: Australia, United States, United Kingdom
Investor stats
- Total investments: 84
- Round size: Seed $600k–$3.5M; Series A $1.6M–$16M; Series B $471k–$22M
- Lead/follow: 23% lead, 77% follow
- Last fund: May invest from a new fund soon — last raise in 2017
Portfolio highlights
- Lucia Bio — Lucia Bio is a biotechnology company that focuses on developing Syk inhibitors that help in the treatment of immunological diseases.
- Tiny Bright Things — Melbourne-based company Tiny Bright Things was cofounded in 2020 by long-time research collaborators Ray Dagastine and Chris Bolton. We invented Halo microscopy to transform the way researchers and manufacturers look at small or transparent things. This helps manufacturers in areas like agrichemicals and pharmaceuticals (where the size and shape ofpowders are critical) and researchers at every stage of discovery— particularly in nanotechnology (where samples are especially tiny) and life sciences (where samples are often also transparent).
- Kinoxis Therapeutics — Developing novel therapeutics for social dysfunction and substance use disorders.
Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff ofthese organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund.A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011.With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position.On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million).Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network.The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Manufacturing
- Stage:Series A, Seed
- Geography: Australia, United States, United Kingdom
Investor stats
- Total investments: 57
- Round size: Seed $381k–$4.2M; Series A $1.3M–$16M
- Lead/follow: 12% lead, 88% follow
- Last fund: May invest from a new fund soon — raised $14M in 2017
Portfolio highlights
- BioScout — Welcome to BioScout, your partner in revolutionizing the agriculture industry with cutting-edge automated disease detection technology for crop growers and viticulture.
- Ferronova — Ferronova is a medical device company that offers imaging and surgery products.
- Morse Micro — Morse Micro is a fast-growing wireless integrated circuit solutions company that is reinventing Wi-Fi for the Internet of Things (IoT). The company was founded by Wi-Fi pioneers and innovators, Michael De Nil and Andrew Terry, joined by the original Wi-Fi inventor Prof. Neil Weste and wireless industry veterans, whose teams designed Wi-Fi chipsinto billions of smartphones. Headquartered in Australia with offices in China and the U.S., Morse Micro’s strong and diverse system team, portfolio of IP and patents, enables Wi-Fi HaLow connectivity across the complete IoT ecosystem, from surveillance systems and access control to industrial automation and mobile devices, allowing connected devices to reach farther. www.morsemicro.com
OneVentures is a later-stage venture capital firm focused on scaling Technology and Healthcare companies through growth equity and credit. The firm's role extends far beyond investment, as the firm actively guides companies toward achieving their next critical milestones. By leveraging decades of global experience and operational expertise,OneVentures accelerates growth and helps shape the future of its portfolio companies.A global growth focus drives their investment selection, with their current portfolio including companies with truly innovative products tackling multi-billion-dollar problems, from needle-free vaccinations to virtual communications to adaptive e-learning.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Debt Financing
- Geography: Australia, United States, Israel
Investor stats
- Total investments: 77
- Round size: Series A $1.5M–$20M; Debt Financing $1M–$6.7M
- Lead/follow: 48% lead, 52% follow
- Last fund: Likely still investing — raised $145M in 2022
Portfolio highlights
- Vaxxas — Vaxxas develops and commercializes needle-free vaccine delivery system. Vaxxas was incorporated in 2011 and is based in Brisbane, Australia.
- Kira Biotech — Kira Biotech is an emerging Australian biotechnology company developing novel immunomodulatory compounds for the treatment of immune system disorders. Its lead candidate, KB312, is a first-in-class, selective, immune-cell depleting monoclonal antibody which targets activated immune cells and aims to restore homeostasis through induction of immunetolerance. Kira Biotech has attracted venture capital funding and is progressing KB312 through preclinical development and phase 1 clinical trials with a team of drug development experts led by well-known US-based rheumatologist and immunologist, Dr Dan Baker.
- Vertero — Axial Therapeutics is a biotechnology company fundamentally changing the treatment of neurological diseases and disorders by harnessing groundbreaking science in the microbiome-gut-brain axis.
Bioplatforms Australia is a non-profit entity that supports life science research in genomic, proteomics, metabolomics, and bioinformatics.
Show more...Investment focus
- Industry: AgTech, Farming, Agriculture
- Stage:Pre-Seed
- Geography: Australia
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Number 8 bio — Number 8 Bio is a scientist-led start-up in Sydney that makes scalable and affordable enteric methane mitigation feed additives for livestock. We have a unique approach to managing rumen energy flows and animal productivity when methane is decreased, and we aim to give farmers a healthy ROI when using the additives.
Build your next company with Antler, a global day zero investor enabling exceptional founders to start great companies, from the very beginning. Apply now!
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Pre-Seed, Seed, Series A
- Geography: Singapore, Australia, United Kingdom
Investor stats
- Total investments: 1197
- Round size: Seed $196k–$5.8M; Pre-Seed $104k–$1.1M; Series A $4.6M–$29M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely actively investing — fresh fund, raised $72M in 2024
Portfolio highlights
- Sapyen — We take the fear out of infertility for men. Test for it at home, without stepping out to the hospital and get personalised health recommendations to improve sperm health and increase your chances of conceiving.
- RubiLabs — RubiLabs Inc provides a platform for unifying, monitoring, and analyzing organizational data. RubiLabs software enables analysts and operators across risk, compliance, and security teams to collaborate and interpret large volumes of information in real time. The company’s platform is designed to help institutions make sense of complex, fragmenteddata by transforming it into a coherent operational picture for risk detection, continuous monitoring, and investigative workflows.
- One Key Access — One Key Access is an interface to the world of couriers to enable 24/7 frictionless deliveries.
Giving Australian founders access to the education, capital and networks needed to build significant, sustainable, global businesses of the future.
Show more...Investment focus
- Industry: Software, Education, Information Technology
- Stage:Pre-Seed, Seed
- Geography: Australia, United States, United Kingdom
Investor stats
- Total investments: 81
- Round size: Seed $135k–$2.3M; Pre-Seed $135k–$500k
- Lead/follow: 83% lead, 17% follow
- Last fund: Likely still investing — raised $18M in 2021
Portfolio highlights
- Paperly — Paperly is an mobile app that provides modules for school management system and learning management system.
- Cor — Obi by Cor is the leading voice AI agent for customer onboarding and user activation. It uses voice and on-screen awareness to guide users, share best practices, and answer questions in real time.
- BarterAds Pty Ltd — BarterAds is a programmatic advertising exchange that enables businesses to acquire customers without cash spend by converting unused ad inventory into a tradable asset. Instead of paying in fiat, companies earn and spend a proprietary internal currency called Barter Dollars, which are issued when they display ads on their owned media propertiessuch as websites, apps, or platforms.The platform operates as an auction-based exchange, similar to traditional ad networks, where advertisers bid for impressions using Barter Dollars. Inventory is matched contextually and priced dynamically through real-time bidding, ensuring efficient allocation of supply and demand across the network. This allows both advertisers and publishers to maximize the value of otherwise underutilized inventory.BarterAds primarily targets startups, SaaS platforms, marketplaces, gaming companies, and content publishers that have traffic but are constrained by rising customer acquisition costs. By removing the need for upfront cash spend, the platform provides a capital-efficient growth channel, particularly for small and mid-sized businesses.The system includes controls for brand safety, fraud prevention, and inventory quality through business verification, campaign approvals, and continuous monitoring. Barter Dollars are non-transferable and expire periodically, preventing hoarding and ensuring continuous circulation within the ecosystem.BarterAds is designed as a hybrid between barter networks and modern ad exchanges, combining the scalability and automation of programmatic advertising with a closed-loop, cashless economy. The company is headquartered in Australia and is focused on building a global network of advertisers and publishers who both contribute inventory and run campaigns within the platform.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Long-term owner-operators of great Australian businesses.
Show more...Investment focus
- Industry: Life Science, Biotechnology, Venture Capital
- Stage:Series A
- Geography: Australia
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Proto Axiom — Early-stage funding to growth capital, we guide scientific breakthroughs from proof-of-concept to commercial success. Our hands-on approach to support Australian research is a first-in-country model.
Medical Research Commercialisation Fund (MRCF) provides dedicated, investment funding to support the commercialisation of early-stage medical research discoveries that originate from its member institutes. The collaborative nature of the MRCF seeks to foster best practice in the commercialisation of medical innovations.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Seed, Series B
- Geography: Australia, United States, United Kingdom
Investor stats
- Total investments: 25
- Round size: Series A $1.3M–$13M; Series B $6.4M–$16M
- Lead/follow: 28% lead, 72% follow
Portfolio highlights
- Denteric — Denteric is developing a vaccine based on research conducted at the University of Melbourne, with collaborative support from CSL Limited, to fight the disease and will receive the money in three parts each year from 2019 to 2021.
- Currus Biologics — Currus Biologics is a biotechnology company that develop CAR-T cell therapies for the treatment of solid tumour cancers.
- Azura Ophthalmics — Azura Ophthalmics is a clinical-stage company that develops an innovative portfolio of compounds to advance treatments for MGD, the leading cause of DED. By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatmentoptions are currently lacking. Azura is underpinned by an experienced management team with an established track record of successfully developing and commercializing novel treatments for ocular surface diseases. The company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the U.S.
Alberici is a diversified construction company recognized for superior quality and customer service. With operations throughout North America and clients around the world, they offer general contracting, construction management, and design-build solutions across a broad spectrum of industrial and commercial markets.
Show more...Investment focus
- Industry: Real Estate, Life Science, Property Management
- Stage:Seed
- Geography: Australia
Investor stats
- Total investments: 1
- Lead/follow: 100% lead, 0% follow
Portfolio highlights
- LCG Capital Management — LCG Capital Management delivers expert real estate solutions, from property management in St. Louis, MO, to asset management & development.
A venture capital fund platform committed to supporting and investing in entrepreneurs and companies developing and bringing exponential technologies to food, health and sustainability. March's investment strategy involves becoming recognized as the leading investor in critical and transformative technology solutions, and aims to achieve thisby investing into companies and funds that focus on developing core intellectual property around game-changing sustainable solutions that are aligned with globally relevant sustainability trends and benefits.
Show more...Investment focus
- Industry: SaaS, Energy, Retail
- Stage:Seed, Series A, Series C
- Geography: United States
Investor stats
- Total investments: 7
- Round size: Seed $4.7M–$4.8M; Series A $7.4M–$33M
- Lead/follow: 29% lead, 71% follow
- Last fund: May invest from a new fund soon — raised $2.1M in 2019
Portfolio highlights
- Digestiva — We amplifye Protein.
- EvodiaBio — Mirroring nature with pioneering bioscience for natural flavors
- Number 8 bio — Number 8 Bio is a scientist-led start-up in Sydney that makes scalable and affordable enteric methane mitigation feed additives for livestock. We have a unique approach to managing rumen energy flows and animal productivity when methane is decreased, and we aim to give farmers a healthy ROI when using the additives.
Alium Capital focuses on listed and unlisted technology investments to generate out-sized returns. The company invests in technology, innovation, and early-stage businesses, all the way through to publicly listed assets. It specializes in the fields of finance, investing, innovation, and capital.Alium Capital was founded in 2016 andheadquartered in Sydney, New South Wales.
Show more...Investment focus
- Industry: Software, Financial Services, Apps
- Stage:Series A, Series B, Seed
- Geography: Australia, United States, Singapore
Investor stats
- Total investments: 39
- Round size: Seed $4.5M–$10M; Series A $500k–$13M; Series B $2M–$465M
- Lead/follow: 49% lead, 51% follow
- Last fund: May invest from a new fund soon — raised $72M in 2017
Portfolio highlights
- Beforepay — Beforepay understands that traditional pay cycles are a form of financial stress. So we set out to find a better way, giving Australians the control and confidence that comes with managing your own money, on your terms.That’s why we created Pay On Demand™ - a service that allows you to access the money you have earned at work, when you choose todo so. After all, it is yours!The app also automatically predicts when your bills are due, shows you how much is OK for you to spend, and automatically creates budgets for you, effortlessly.
- Academy Xi — At Academy Xi, we help APAC's largest and most sophisticated organisations optimise performance with concise, actionable training solutions.
- DesignCrowd — Crowdsourced logo, freelance graphic and web design at DesignCrowd. 1,328,201 freelance designers compete to create amazing designs for your business. Start Today!
The Breakthrough Victoria Fund is a $2 billion investment by the Victorian Government to drive investment in research and innovation.
Show more...Investment focus
- Industry: Health Care, Manufacturing, Biotechnology
- Stage:Seed, Series A
- Geography: Australia, United States, Philippines
Investor stats
- Total investments: 48
- Round size: Seed $708k–$7.1M; Series A $1.8M–$36M
- Lead/follow: 58% lead, 42% follow
Portfolio highlights
- World View Enterprises — World View sets the standard for stratospheric exploration via remote sensing, C4ISR and asset monitoring via stratospheric balloons, along with future space tourism and research and education offerings.
- RayGen — We're powering the future with low cost, high efficiency solar power technology and renewable energy storage. Contact us for more details today.
- Conflux Technology — Conflux Technology is a new generation of heat exchangers made by metal additive manufacturing (3D printing).
A grant program offered by AusIndustry as part of the Australian Government’s National Innovation and Science Agenda
Show more...Investment focus
- Industry: Software, Mining, Hardware
- Stage:Grant, Pre-Seed
- Geography: Australia
Investor stats
- Total investments: 2
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Neuromersiv — Combining Virtual Reality, haptics and functional electrical stimulation, Neuromersiv is revolutionising brain rehabilitation therapy.Using a proprietary wearable device paired with a VR headset, Neuromersiv provides an engaging, immersive therapy experience in which patients perform gamified tasks ranging from picking up a toothbrush to climbingEverest! This unique approach increases dopamine activity in the brain, enhancing neuroplasticity, which is the brain’s ability to form new neural connections. Early trials of Neuromersiv technology have demonstrated 3x better outcomes as compared to traditional rehabilitation therapy resulting in faster independence and reduced care costs.
- Tiny Bright Things — Melbourne-based company Tiny Bright Things was cofounded in 2020 by long-time research collaborators Ray Dagastine and Chris Bolton. We invented Halo microscopy to transform the way researchers and manufacturers look at small or transparent things. This helps manufacturers in areas like agrichemicals and pharmaceuticals (where the size and shape ofpowders are critical) and researchers at every stage of discovery— particularly in nanotechnology (where samples are especially tiny) and life sciences (where samples are often also transparent).
Catalio Capital Management was created by George Petrocheilos and Dr. Jacob Vogelstein to invest in breakthrough biomedical technology companies created or referred by Catalio Capital Management, an elite group of world-renowned, serial scientist-entrepreneurs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Life Science
- Stage:Series A, Series B
- Geography: United States, Switzerland, Israel
Investor stats
- Total investments: 116
- Round size: Series A $18M–$120M; Series B $26M–$150M
- Lead/follow: 28% lead, 72% follow
Portfolio highlights
- Avava — Avava is a Pioneer precision skin therapy to improve the quality of life for patients around the world.
- OSPRI — Multiplex qPCR reagent kits for assay development, biomarker discovery, and translational research. 120+ configurations across a broad range of research areas. Extraction-free. Customizable. For Research Use Only.
- Medical Informatics — Medical Informatics offers solutions that give care teams access to the data they need to take action for alarm management and safety. The company’s Sickbay software platform enables continuous data collection from a comprehensive set of devices. Ultimately their alarm management solutions reduce alarm noise at the patient level, and send the rightalarms to care providers.Medical Informatics Corp was founded by Emma Fauss and Craig Rusin in 2010 and is based in Houston, Texas.
Flintco provides innovative construction solutions with an unrelenting focus on quality, safety, cost and schedule.
Show more...Investment focus
- Industry: Real Estate, Life Science, Property Management
- Stage:Seed
- Geography: Australia
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- LCG Capital Management — LCG Capital Management delivers expert real estate solutions, from property management in St. Louis, MO, to asset management & development.
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Togetherwith its wholly-owned subsidiary, Pharmacyclics, AbbVie employs ~29,000 people worldwide and markets medicines in more than 175 countries.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, China, Italy
Investor stats
- Total investments: 49
- Round size: Series A $6M–$53M; Series B $12M–$85M; Series C $39M–$115M
- Lead/follow: 16% lead, 84% follow
Portfolio highlights
- Mozart Therapeutics — The company intended to focus on developing novel immune engagers.
- Quanta Therapeutics — Quanta is a biotechnology company uncovering novel cancer therapeutic candidates using allosteric modulation to target driver oncogenes. The company was founded in 2018 and is based in San Francisco, CA.
- DISCO Pharmaceuticals — DISCO Pharmaceuticals is a firm that specializes in large-scale surfaceome unlocking of cancer cells.
Life Science VC funding in Australia at a glance
Stats across 28 deals from 39 investors.
Access all 39 VC funds in Australia Life Science startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Life Science VC Funds in Australia investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 39 VC funds investing in Australia Life Science startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!